71 related articles for article (PubMed ID: 2545335)
21. Dipyridamole enhancement of drug sensitivity in acute lymphoblastic leukemia cells.
Sotomatsu M; Yugami S; Shitara T; Kuroume T
Am J Hematol; 1993 Aug; 43(4):251-5. PubMed ID: 8372807
[TBL] [Abstract][Full Text] [Related]
22. Etoposide-induced cytotoxicity in two human T-cell leukemic lines: delayed loss of membrane permeability rather than DNA fragmentation as an indicator of programmed cell death.
Catchpoole DR; Stewart BW
Cancer Res; 1993 Sep; 53(18):4287-96. PubMed ID: 8364925
[TBL] [Abstract][Full Text] [Related]
23. Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding.
Curtin NJ; Bowman KJ; Turner RN; Huang B; Loughlin PJ; Calvert AH; Golding BT; Griffin RJ; Newell DR
Br J Cancer; 1999 Aug; 80(11):1738-46. PubMed ID: 10468290
[TBL] [Abstract][Full Text] [Related]
24. Dipyridamole potentiates adriamycin cytotoxicity by a mechanism other than inhibiting nucleoside uptake.
Kusumoto H; Maehara Y; Anai H; Kumashiro R; Sugimachi K
Anticancer Res; 1991; 11(4):1539-42. PubMed ID: 1746911
[TBL] [Abstract][Full Text] [Related]
25. Potentiation of etoposide-induced DNA damage by calcium antagonists in L1210 cells in vitro.
Yalowich JC; Ross WE
Cancer Res; 1984 Aug; 44(8):3360-5. PubMed ID: 6744270
[TBL] [Abstract][Full Text] [Related]
26. Synergistic effect of prochlorperazine and dipyridamole on the cellular retention and cytotoxicity of doxorubicin.
Krishan A; Sridhar KS; Mou C; Stein WD; Lyubimov E; Hu YP; Fernandez H
Clin Cancer Res; 2000 Apr; 6(4):1508-17. PubMed ID: 10778983
[TBL] [Abstract][Full Text] [Related]
27. Modulation of etoposide cytotoxicity and DNA strand scission in L1210 and 8226 cells by polyamines.
Dorr RT; Liddil JD; Gerner EW
Cancer Res; 1986 Aug; 46(8):3891-5. PubMed ID: 3015379
[TBL] [Abstract][Full Text] [Related]
28. Effects of nucleoside transport inhibitors on the salvage and toxicity of adenosine and deoxyadenosine in L1210 and P388 mouse leukemia cells.
Plagemann PG; Wohlhueter RM
Cancer Res; 1985 Dec; 45(12 Pt 1):6418-24. PubMed ID: 3877568
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the inhibitory effects of VP-16-213 (etoposide) and podophyllotoxin on thymidine transport and metabolism in Ehrlich ascites tumor cells in vitro.
Yalowich JC; Goldman ID
Cancer Res; 1984 Mar; 44(3):984-9. PubMed ID: 6692420
[TBL] [Abstract][Full Text] [Related]
30. Synergistic inhibition of growth of breast and colon human cancer cell lines by site-selective cyclic AMP analogues.
Tagliaferri P; Katsaros D; Clair T; Ally S; Tortora G; Neckers L; Rubalcava B; Parandoosh Z; Chang YA; Revankar GR
Cancer Res; 1988 Mar; 48(6):1642-50. PubMed ID: 2830966
[TBL] [Abstract][Full Text] [Related]
31. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells.
Zhou Z; Zwelling LA; Kawakami Y; An T; Kobayashi K; Herzog C; Kleinerman ES
Cancer Res; 1999 Sep; 59(18):4618-24. PubMed ID: 10493516
[TBL] [Abstract][Full Text] [Related]
32. Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C.
Ritke MK; Murray NR; Allan WP; Fields AP; Yalowich JC
Mol Pharmacol; 1995 Nov; 48(5):798-805. PubMed ID: 7476909
[TBL] [Abstract][Full Text] [Related]
33. Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II.
Campain JA; Padmanabhan R; Hwang J; Gottesman MM; Pastan I
J Cell Physiol; 1993 May; 155(2):414-25. PubMed ID: 8097746
[TBL] [Abstract][Full Text] [Related]
34. The combination of different types of antitumor topoisomerase II inhibitors, ICRF-193 and VP-16, has synergistic and antagonistic effects on cell survival, depending on treatment schedule.
Ishida R; Iwai M; Hara A; Andoh T
Anticancer Res; 1996; 16(5A):2735-40. PubMed ID: 8917380
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of herpes simplex virus reactivation by dipyridamole in a mouse model.
Hay KA; Gaydos A; Tenser RB
J Med Virol; 1996 Oct; 50(2):198-203. PubMed ID: 8915888
[TBL] [Abstract][Full Text] [Related]
36. Inhibitory effects of dipyridamole on growth, nucleoside incorporation, and platelet-activating capability in the U87MG and SKNMC human tumor cell lines.
Bastida E; del Prado J; Almirall L; Jamieson GA; Ordinas A
Cancer Res; 1985 Sep; 45(9):4048-52. PubMed ID: 2992771
[TBL] [Abstract][Full Text] [Related]
37. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of dipyridamole's action in inhibition of venous and arterial smooth muscle cell proliferation.
Zhuplatov SB; Masaki T; Blumenthal DK; Cheung AK
Basic Clin Pharmacol Toxicol; 2006 Dec; 99(6):431-9. PubMed ID: 17169124
[TBL] [Abstract][Full Text] [Related]
39. Dipyridamole reverses the resistance to topoisomerase II inhibitors but not to antimicrotubule agents in multidrug-resistant melanoma cells.
Damle B; Desai P
Oncol Res; 1994; 6(2):49-57. PubMed ID: 7949465
[TBL] [Abstract][Full Text] [Related]
40. Etoposide enhances the antitumor effects of cisplatin in gastric cancer cells.
Hotta T; Tanimura H; Yamaue H; Iwahashi M; Tani M; Tsunoda T; Noguchi K; Mizobata S; Arii K; Terasawa H
Anticancer Res; 1997; 17(2A):885-9. PubMed ID: 9137422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
